Friday , November 22 2019
Home / zimbabwe / Information update – Mylan-Valsartan medications voluntarily annoyed as a result of an annoyance

Information update – Mylan-Valsartan medications voluntarily annoyed as a result of an annoyance



OTTAWA, Nov. 28, 2018/ CNW / –

Issue:
Mylan ULC Pharmacy voluntarily includes four Mylan-Valsartan tablets (40 mg, 80 mg, 160 mg and 320 mg strength). After examinations, they found an approximate inertia, N-nitrosodietilamine (NDEA).

Valsartan is a drug Patients with high blood pressure help to prevent heart attacks and strokes. It is also used in patients with heart failure or heart failure.

The products are considered as precautionary measures. When the NDEA level is found in the active pharmaceutical component (valsartan), it is manufactured by Mylan Laboratories Limited IndiaThey are low, because they are reasonably safe, drugs were taken throughout life. As regards the durability of the affected products in the Canadian market, it must be carefully considered.

Last recall of recent reminders and other actions In Canada NDEA and other inputs, N-nitrosodimethylamine (NDMA), after finding certain drugs (see the links below for related communications). NDEAs and NDMAs are classified as probable human carcinomas, which means that long-term exposure can increase the risk of cancer.

Health Canada continues working with international regulatory partners to determine the scope and creation of the topic, and to confirm the necessary actions and ensure that there is no incident. They will remember these areas. Additional security concerns should be identified, Canada Health will take appropriate measures and notify Canadians.

There is no shortage in anticipation of this progress, there are alternative products in the Canadian market. As with previous NDMA and NDMA communications, Health Canada advice recommends that patients have no risk of taking these medications, the risk of cancer with regard to long-term impurities. Patients should not refrain from taking their medication if they do not have any healthcare provider advice.

What consumers need to do

  • Follow your valsartan medication except You have been advised to stop your healthcare assistants.
  • Contact your healthcare provider to discuss the treatment option if you have used the damaged product.
  • Ask your pharmacist if you are not sure if you have taken the product you have recalled.
  • Contact your healthcare provider with a reminder product and have concerns about your health.
  • Contact Mylan by calling 1-800-575-1379 at recall@mylan.ca.
  • Report any health or environmental product complaint to Canada Health.

Affected products

The following Mylan valsartan products are being recalled.

(Note: There is a list of non-foreseeable pre-planned products in the previous valsartan list).

Product name / Active
Pharmaceutical ingredients

Strength

DIN

Lot

MYLAN-Valsartan

40 mg

02383527

3048813-1

MYLAN-Valsartan

80 mg

02383535

3056368

MYLAN-Valsartan

160 mg

02383543

3056371

MYLAN-Valsartan

320 mg

02383551

3048815-1

Related links

Keep online Get Healthcare Canada and the latest tips and product reminders.

French is also available

SOURCE Health Canada


Source link